Comparative study of full dose neoadjuvant chemotherapy response, among breast cancer and axillary metastasis, according to immunohistochemistry results, at Senology Center of Hospital Amaral Carvalho in Jaú, SP

Abstract

Objective: The study aimed to verify the differences among the response of primary tumor and axillary metastasis, as well the global response, after neoadjuvant chemotherapy, correlating immunohistochemistry subtypes currently used at this service. Methods: Observational, retrospective study, collected from medical record data of 100 patients with breast cancer treated at Senology Center of Hospital Amaral Carvalho, Brazil, with staging IIIA, IIIB e IIIC, submitted to neoadjuvant chemotherapy and subsequent surgery, from January 2011 to July 2012. Results: From the universe of 100 patients with breast cancer submitted to neoadjuvant chemotherapy, 7 were excluded for the absence of immunohistochemistry. A total of 93 patients presented injury in breast and axilla, 70 (75.25%) of them acquired clinicopathological response, being 57 (61.29%) with partial response and 13 (13.9%) with complete pathological response. From 57 patients with partial response, 30 (32.25%) still presented injury in breast and axilla and 27 (29%) presented injury in breast but not in axilla. From the four immunohistochemistry subtypes verified (luminal A/B, hybrid luminal, triple negative and HER-2) the best results were watched in triple negative patients, showing the larger rate of partial response and complete pathological response of the disease. Conclusion: We may conclude that neoadjuvant chemotherapy has a positive effect over locally advanced breast cancer, especially in triple negative patients. In this subtype, we find out more agreement of negative response among primary tumor and axilla.